Cited 9 times in
Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김승일 | - |
dc.contributor.author | 정준 | - |
dc.date.accessioned | 2024-01-16T01:58:19Z | - |
dc.date.available | 2024-01-16T01:58:19Z | - |
dc.date.issued | 2023-11 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/197807 | - |
dc.description.abstract | PURPOSE: To determine the updated long-term outcomes of the Addition of Ovarian Suppression to Tamoxifen in Young Women With Hormone-Sensitive Breast Cancer Who Remain Premenopausal or Regain Vaginal Bleeding After Chemotherapy (ASTRRA) trial. PATIENTS AND METHODS: This study is a post-trial follow-up of the ASTRRA trial, involving 1,483 premenopausal women younger than 45 years treated with definitive surgery after completing adjuvant or neoadjuvant chemotherapy for estrogen receptor-positive breast cancer. Patients were randomly assigned in a 1:1 ratio to complete 5 years of tamoxifen (TAM) alone (TAM-only) or 5 years of TAM with ovarian function suppression (OFS) for 2 years (TAM + OFS). The primary end point was disease-free survival (DFS), and the secondary end point was overall survival (OS). RESULTS: At 106.4 months of median follow-up, there was a continuous significant reduction in the DFS event rate in the TAM + OFS group. The 8-year DFS rate was 85.4% in the TAM + OFS group and 80.2% in the TAM-only group (hazard ratio [HR], 0.67; 95% CI, 0.51 to 0.87). There were no significant differences in OS between the two groups. The OS rate was 96.5% in the TAM + OFS group and 95.3% in the TAM-only group (HR, 0.78; 95% CI, 0.49 to 1.25). CONCLUSION: Adding OFS for 2 years to adjuvant TAM with a longer follow-up resulted in consistent DFS benefits, suggesting that adding OFS to TAM should be considered for patients who remain in a premenopausal state or resume ovarian function after chemotherapy. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | American Society of Clinical Oncology | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antineoplastic Agents, Hormonal / adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / adverse effects | - |
dc.subject.MESH | Breast Neoplasms* | - |
dc.subject.MESH | Chemotherapy, Adjuvant / adverse effects | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Ovary | - |
dc.subject.MESH | Premenopause | - |
dc.subject.MESH | Tamoxifen* / adverse effects | - |
dc.title | Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Soo Yeon Baek | - |
dc.contributor.googleauthor | Woo Chul Noh | - |
dc.contributor.googleauthor | Sei-Hyun Ahn | - |
dc.contributor.googleauthor | Hyun-Ah Kim | - |
dc.contributor.googleauthor | Jai Min Ryu | - |
dc.contributor.googleauthor | Seung Il Kim | - |
dc.contributor.googleauthor | Eun-Gyeong Lee | - |
dc.contributor.googleauthor | Seock-Ah Im | - |
dc.contributor.googleauthor | Yongsik Jung | - |
dc.contributor.googleauthor | Min Ho Park | - |
dc.contributor.googleauthor | Kyong Hwa Park | - |
dc.contributor.googleauthor | Su Hwan Kang | - |
dc.contributor.googleauthor | Joon Jeong | - |
dc.contributor.googleauthor | Eunhwa Park | - |
dc.contributor.googleauthor | Sung Yong Kim | - |
dc.contributor.googleauthor | Min Hyuk Lee | - |
dc.contributor.googleauthor | Lee Su Kim | - |
dc.contributor.googleauthor | Woosung Lim | - |
dc.contributor.googleauthor | Seonok Kim | - |
dc.contributor.googleauthor | Hee Jeong Kim | - |
dc.identifier.doi | 10.1200/JCO.23.00557 | - |
dc.contributor.localId | A00658 | - |
dc.contributor.localId | A03727 | - |
dc.relation.journalcode | J01331 | - |
dc.identifier.eissn | 1527-7755 | - |
dc.identifier.pmid | 37607321 | - |
dc.identifier.url | https://ascopubs.org/doi/10.1200/JCO.23.00557 | - |
dc.contributor.alternativeName | Kim, Seung Il | - |
dc.contributor.affiliatedAuthor | 김승일 | - |
dc.contributor.affiliatedAuthor | 정준 | - |
dc.citation.volume | 41 | - |
dc.citation.number | 31 | - |
dc.citation.startPage | 4864 | - |
dc.citation.endPage | 4871 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL ONCOLOGY, Vol.41(31) : 4864-4871, 2023-11 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.